This edition presents key opinion leader (KOL) views on recent developments in the ovarian cancer market. Topics covered include: AstraZeneca and Merck & Co. announcing the extended approval in the US to the label of...

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; data released from Bristol-Myers Squibb’s Phase III CheckMate-214 study,...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson...

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY...

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche...

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; Anthera Pharmaceuticals announcing that it has commenced...

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...